Indigenous Bloom Hemp Past Earnings Performance
Past criteria checks 0/6
Indigenous Bloom Hemp's earnings have been declining at an average annual rate of -71.9%, while the Pharmaceuticals industry saw earnings growing at 25% annually.
Key information
-71.9%
Earnings growth rate
34.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 28 Feb 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Indigenous Bloom Hemp makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 28 Feb 23 | 0 | -2 | 0 | 0 |
| 30 Nov 22 | 0 | -2 | 0 | 0 |
| 31 Aug 22 | 0 | -8 | 0 | 0 |
| 31 May 22 | 0 | -2 | 0 | 0 |
| 28 Feb 22 | 0 | -1 | 0 | 0 |
| 30 Nov 21 | 0 | -1 | 0 | 0 |
| 31 Aug 21 | 0 | 6 | 0 | 0 |
| 31 May 21 | 0 | 0 | 0 | 0 |
Quality Earnings: IBH is currently unprofitable.
Growing Profit Margin: IBH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IBH's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare IBH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IBH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (100.1%).
Return on Equity
High ROE: IBH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.